CART Disease Outlook [2017] [Report Updated: 01062017] Prices from USD $8145

05:29 EDT 1 Jul 2017 | BioPortfolio Report Blog

Will CART cell therapies shape the treatment of blood cancers in the next decade?

AntiCD19 CART cell therapies have demonstrated unprecedented response rates across patient subgroups of acute lymphocytic leukaemia ALL and nonHodgkin lymphoma NHL with high unmet needs. How will the impressive efficacy and safety of these therapies pan out in the longterm? Key opinion leaders KOLs explore the clinical challenges and opportunities that face these exciting treatments across multiple haematological cancer settings. Experts discuss the logistical, pricing, reimbursement and market access PRMA hurdles facing these novel therapies and how they can be overcome. Learn how KOLs see the future CART therapy market evolving, and how they expect developers to successfully differentiate their CART therapies in KOL Insight: CART cell Therapy in Haematological Malignancy. Eight US KOLs also provide their candid views on the potential for nextgeneration approaches, allogeneic CART therapies and other novel strategies

Take a tour of the report now:

The table of contents >
The key business questions answered >
The key KOL quotes >
See the therapies covered >
Find out who the KOLs are >
Review an extract from the report 1 drug profile >

Top Takeaways

Impressive responses achieved with antiCD19 CART but how important is longterm durability? Efficacy is unprecedented in relapsed/refractory patients with high unmet needs but how do KOLs view the longterm durability and persistence of CART therapies?
Which diseases show most benefit to CART treatment and why? AntiCD19 CART cells have been investigated in acute lymphocytic leukaemia ALL, chronic lymphocytic leukaemia CLL, nonHodgkin lymphoma NHL. What are the key opportunities facing CART in each disease and which ones are KOLs most excited about?
What needs to be prioritised in terms of safety? Cytokine release syndrome CRS and neurotoxicity are associated with CART treatment. How concerned are KOLs about safety of these treatments and how will side effects be managed going forward?
What are the main logistical challenges facing autologous CART cell therapies and how can they be overcome? Find out what logistical hurdles face autologous CART cell therapies and what KOLs think can be done to overcome them.
Pricing, reimbursement and market access of CART cell therapy; what are KOL's opinions? What key market barriers will CART therapies face and will payers be prepared to fund them?
Do nextgeneration CART cell approaches ignite KOL excitement? Allogeneic offtheshelf' CART cells and CART cells incorporating safety switches are all in the earlystage pipeline. Which approach do KOLs think offers most promise and why?
How do CART cell therapies compare to goldstandard transplantation? Haematopoietic stem cell transplants HSCT are a cornerstone of treatment in haematological cancer. What parallels can KOLs draw from HSCT and do experts envisage CART cell therapies eventually replacing transplantation?
Which key players are best positioned for commercial success and why? Competition is mounting between Novartis, Kite Pharma and Juno Therapeutics but which key player is best positioned to carry CART cell therapies forward according to the KOLs?
How can companies differentiate themselves to market CART therapies? What do CART manufacturers need to do in order to bring these therapies to market in a competitive landscape?
How will CART cell therapies impact the future treatment algorithms of haematological cancers in 10 to 15 years? Can CART therapies fulfil unmet needs and secure a niche in future treatment landscapes?


The response is impressive enough that I see [CART therapies] being around in 10 to 15 years. Exactly where to use them and when to use them is still unknown. I see them being used for lymphoma, ALL, and in multiple myeloma, we'll have to see.US Key Opinion Leader

The responses for ALL are unprecedented. Somewhere between 80 to 90 percent of patients achieve a complete remission, and that's across different CAR programmes, and so it really does tell you it's a feature of the technology and not some secret at one company or one institution over another.US Key Opinion Leader

A report based on expert knowledge

Key Opinion Leaders Interviewed for This Report

North American KOLs

Sample of therapies covered

Pipeline Therapies

tisagenlecleucelT CTL019; Novartis
axicabtagene ciloleucel KTE019; Kite Pharma
JCAR014 Juno Therapeutics
JCAR017 Juno Therapeutics
JCAR018 Juno Therapeutics
UCARTs Cellectis/Pfizer/Cellectis
Plus 4 more Download the complete list here >

Sample of KOLs interviewed

KOLs from North America

Professor Michael R. Bishop, MD. Professor of Medicine and Director of Hematopoietic Stem Cell Transplantation Program at the University of Chicago.
Dr. Marco L. Davila, MD, PhD. Medical oncologist in the Department of Blood and Marrow Transplantation at the Moffitt Cancer Center, Florida.
Dr. Noelle Frey, MD, MSCE. Assistant Professor of Medicine at the Hospital of the University of Pennsylvania.
Plus 4 more Download the complete list here >

Money Back Guarantee

At FirstWord, we stand behind our reports. If you're not completely satisfied, we'll refund your money. Guaranteed.

About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering uptotheminute pharma news, insight, analysis and expert views of importance to your company's success.

FirstWord Reports deliver timely, needtoknow intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Original Article: CART Disease Outlook [2017] [Report Updated: 01062017] Prices from USD $8145


More From BioPortfolio on "CART Disease Outlook [2017] [Report Updated: 01062017] Prices from USD $8145"

Quick Search